Germany - Drugs

Description

The subject of this publication is the conclusion of non-exclusive rebate agreements pursuant to Section 130a (8) SGB V for drugs containing the active ingredient lacosamide (ATC code according to WHO: N03AX18). The contract is concluded within the framework of a so-called open house model, i.e. a contract conclusion is open to all interested pharmaceutical companies within the participation period, provided they fulfill and accept the participation requirements. As a consequence, individual contract negotiations are not conducted and (supply) exclusivity is not given. It should be noted that the purchase quantity is unknown, as it depends on demand and the development of the number of insured persons, the prescription behavior of physicians, and the dispensing and stocking behavior of public pharmacies. Accordingly, minimum purchase quantities are not guaranteed. For further information, please refer to point II.2.4) of the announcement.
Interested pharmaceutical companies can download the participation documents via the project room of the German Procurement Portal (DTVP). For this purpose, an application for access to the project room is first required. Once access has been granted by the contracting authority, the participation documents can then be accessed. The documents to be submitted can be found in the "Cover Letter" and "Explanation of Contract Terms" documents stored in the Project Space. Communication, including transmission of the participation documents, will take place electronically via the DTVP award portal; details of this can be found in the aforementioned documents. Any information to the contrary in the contract notice is due to technical reasons and is not binding.Requests to participate may be submitted for the first time until December 5, 2022.For all other submission deadlines, please refer to the "Submission Deadlines" attachment in the Project Space. If the day of the submission deadline falls on a Saturday, Sunday or national public holiday, the next working day shall take the place of such a day. In the event of late receipt, the submitted requests to participate will be considered for the next submission deadline. The contracting authority reserves the right to request the pharmaceutical companies to submit, complete or correct missing, incomplete or incorrect documents (in particular declarations, information and evidence) in compliance with the principles of transparency and equal treatment (subsequent request). The documents shall be submitted by the pharmaceutical entrepreneur upon request by the contracting agency within a period determined by the calendar. If the requested documents are not submitted within the deadline, the application for participation may be excluded or not considered until the next submission deadline.The rebate agreement ends, regardless of the date of the conclusion of the agreement, no later than December 31, 2024.The contracting authority reserves the right to terminate the open house procedure prematurely, in particular in the event of the conclusion of exclusive rebate agreements; in this case, the rebate agreements already concluded shall end in accordance with the contractual provisions. According to the experience of the contracting authority, exclusive discount agreements usually enter into force 8 to 12 months after publication of the corresponding contract notice in the Supplement to the Official Journal of the European Union.

Opportunity closing date

31 December 2024

Value of contract

to be confirmed